Skip to main content
Fig. 2 | Orphanet Journal of Rare Diseases

Fig. 2

From: Patient and observer reported outcome measures to evaluate health-related quality of life in inherited metabolic diseases: a scoping review

Fig. 2

HrQoL assessment studies VS approved therapies in IMDs; Legend: Graph showing the number of HrQoL assessment studies (light blue) and approved therapies (dark blue) for the IMDs included in this review over time. The number of approved therapies is based on a specific search including EMA (http://www.ema.europa.eu), FDA (https://www.fda.gov) and Clinical Trials.gov (https://clinicaltrials.gov)

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172